Investigation of V520 in an HIV Vaccine Proof-of-Concept Study - Full Text View

Investigation of V520 in an HIV Vaccine Proof-of-Concept Study

This study has been terminated.

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00095576

Purpose

This study will test the safety and efficacy of V520 HIV vaccine. Efficacy will be measured by either prevention of HIV infection or control of HIV viral load in subjects who become HIV infected.

Condition	Intervention	Phase
AIDS HIV Infections	Biological: V520	Phase II

MedlinePlus related topics:

AIDS

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study

Further study details as provided by Merck:

Study Start Date:

December 2004

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy, HIV seronegative adults at high risk of acquiring HIV infection.
Cannot have previously received an investigational vaccine

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00095576

Sponsors and Collaborators

Merck

Investigators


Study Director:	Medical Monitor	Merck

More Information

Click here for more information about this trial This link exits the ClinicalTrials.gov site

Study ID Numbers:	2004_091
First Received:	November 5, 2004
Last Updated:	September 26, 2007
ClinicalTrials.gov Identifier:	NCT00095576
Health Authority:	United States: Food and Drug Administration